Literature DB >> 18721206

Ejaculatory dysfunction caused by the new alpha1-blocker silodosin: A preliminary study to analyze human ejaculation using color Doppler ultrasonography.

Atsushi Nagai1, Ryoei Hara, Teruhiko Yokoyama, Yoshimasa Jo, Tomohiro Fujii, Yoshiyuki Miyaji.   

Abstract

OBJECTIVES: In order to clinically investigate the mechanism of ejaculatory dysfunction attributable to the alpha1-blocker silodosin, a real-time observation of ejaculation by healthy males was performed.
METHODS: Following intake of silodosin, a newly developed selective alpha1-blocker for benign prostatic hypertrophy, ejaculation was dynamically observed using color Doppler ultrasound in three healthy males. Normal ejaculation was also investigated in the same manner.
RESULTS: With silodosin intake, no antegrade ejaculation was observed in cases 1 or 2. In case 1, seminal fluid slowly but continuously flowed out from the seminal vesicles into the bladder. In case 2, only a small amount of seminal fluid flowed into the bladder during the ejaculatory sensation. In case 3, ejection of a small amount of semen from the external urethral orifice was observed and inflow of a small amount of seminal fluid into the bladder was also captured. Without silodosin intake, all three subjects exhibited antegrade ejaculation.
CONCLUSIONS: The mechanism of ejaculatory dysfunction is intricately related to retrograde ejaculation (retrograde inflow of seminal fluid), insufficient contraction of the seminal vesicles, and insufficient rhythmic contraction of the muscles of the pelvic floor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18721206     DOI: 10.1111/j.1442-2042.2008.02136.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  11 in total

1.  Sexual impact of treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.

Authors:  Herbert J Wiser; Tobias S Köhler
Journal:  Curr Urol Rep       Date:  2010-07       Impact factor: 3.092

Review 2.  Update on the sexual impact of treatment for benign prostatic hyperplasia.

Authors:  John Roger Bell; Eric Laborde
Journal:  Curr Urol Rep       Date:  2012-12       Impact factor: 3.092

Review 3.  Impact of alpha blockers, 5-alpha reductase inhibitors and combination therapy on sexual function.

Authors:  Charles Welliver; Michael Butcher; Yogitha Potini; Kevin T McVary
Journal:  Curr Urol Rep       Date:  2014-10       Impact factor: 3.092

4.  Male squirting: Analysis of one case using color Doppler ultrasonography.

Authors:  Ryoei Hara; Atsushi Nagai; Tohta Nakatsuka; Shin Ohira; Tomohiro Fujii; Yoshiyuki Miyaji
Journal:  IJU Case Rep       Date:  2018-10-10

Review 5.  Measurement of benign prostatic hyperplasia treatment effects on male sexual function.

Authors:  T A Skolarus; J T Wei
Journal:  Int J Impot Res       Date:  2009-06-18       Impact factor: 2.896

Review 6.  The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia.

Authors:  Jason Gandhi; Steven J Weissbart; Noel L Smith; Steven A Kaplan; Gautam Dagur; Anna Zumbo; Gargi Joshi; Sardar Ali Khan
Journal:  Transl Androl Urol       Date:  2017-04

Review 7.  Clinical review of ejaculatory dysfunction.

Authors:  Toshikazu Otani
Journal:  Reprod Med Biol       Date:  2019-07-24

8.  Orgasm is preserved regardless of ejaculatory dysfunction with selective alpha1A-blocker administration.

Authors:  K Kobayashi; N Masumori; R Kato; S Hisasue; R Furuya; T Tsukamoto
Journal:  Int J Impot Res       Date:  2009-06-18       Impact factor: 2.896

9.  Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia.

Authors:  Koichi Sakata; Tatsuo Morita
Journal:  BMC Urol       Date:  2012-10-19       Impact factor: 2.264

10.  Physiological and pharmacological aspects of the vas deferens-an update.

Authors:  David S Koslov; Karl-Erik Andersson
Journal:  Front Pharmacol       Date:  2013-08-22       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.